Underweight: 30% trim at $390-395, hold 70% core, hard stop $370, re-entry gated on olpasiran Phase 3 + dual confirmation
The 30% trim is operationally superior: it meaningfully reduces binary catalyst risk without abandoning structural support at $356 per the 9/11 binding lesson. The $370 stop (below basing floor, above 200 SMA at $356.77) preserves 200 SMA test optionality while defining maximum loss. Dual confirmation re-entry (MACD cross AND 50 SMA reclaim with volume >5M) addresses repeated failed reclaim attempts since 9/8. Pre-binary-event re-entry prohibition prevents the knife-catching mistake. At 0.43 beta and 2.6% dividend, passive retention accumulates alpha decay against SPY recovery in a defensive-rotation regime, making Underweight superior to Hold per the 9/16 reflection. The 9/11 Underweight lesson prohibits sizing beyond 15-20% trim ahead of 200 SMA test, making full Sell inappropriate with $14B cash, Imdelltra +115% sales growth, and MariTide Phase 3 optionality intact.
| Position | Action |
|---|---|
| Current price $390-395 | Trim 30% of position, preserving 70% core |
| Close below $370 | Hard stop triggered (below basing floor, preserves 200 SMA test optionality) |
| $356 weekly close | Trim escalation to 50-55% (categorical invalidation of thesis) |
| Elevated implied volatility environment | No collar: trim + stop defines ~5% position risk more efficiently than collar overlay |
Amgen presents an asymmetric long opportunity at current basing levels, with technicals showing a coiled-spring setup within an intact uptrend, fundamentals accelerating with 32% operating income growth and a compelling 16.11x forward P/E, and pipeline catalysts like MariTide and IMDELLTRA that the market is mispricing as tail risks rather than upside.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $356.77 | bullish |
| close_50_sma | $399.55 | bearish |
| close_10_ema | $390.97 | bullish |
| macd | -7.84 | bearish |
| macds | -3.46 | bearish |
| macdh | -4.38 | bearish |
| rsi | 45.12 | neutral |
| boll | $411.22 | neutral |
| boll_ub | $468.98 | neutral |
| boll_lb | $353.46 | neutral |
| vwma | ~$395.36 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Olpasiran Phase 3 readout must clear before adding new positions
Then: Do not add before binary catalyst confirmation
EV: +21-26% · concedes: Bear notes 15% washout in 9 days; Bear points to 50 SMA at $399.55 with price below resistance, momentum broken; Bear highlights P/E 24.45x and PEG 2.32 as expensive; Bear circles back to pelacarsen read-across for olpasiran; Bear waves D/E ratio of 490% as red flag
AMGN is a fairly-valued, high-leverage, patent-cliff-exposed biotech stuck below its medium-term trend with binary pipeline event overhead and no retail momentum to cushion a downside move—the asymmetric setup is actually a trap with downside skew closer to 2-to-1 when properly framed.
EV: $345–$365 (7–12% downside) · concedes: Q2 2026 was a solid quarter: $9.54B revenue, $4.37 diluted EPS, 35.5% operating margin; 2.61% dividend yield provides some income support; Cash position grew from $8.03B to $13.99B (74% YoY)
→ vs conservative: 2.6% yield and 0.426 beta are not a defensive shield — yield is mediocre vs. S&P total returns, low beta causes underperformance during risk-on rotations, and debt load ($43B net, 490% D/E) makes the 'fortress' narrative false; income alone doesn't justify position when total-return outlook is negative
→ vs conservative: Goodwill at 41% of assets is a 'ticking time bomb' — any Horizon pipeline failure triggers impairment that hits earnings directly; this is a leveraged biotech dressed in blue-chip clothing, not a defensive bond proxy
→ vs neutral: Waiting for confirmation on broken medium-term trend causes you to give back gains; neutral thesis of 'fair value, balanced risk-reward, wait for catalysts' is 'the classic Wall Street compromise that gets you nowhere'
→ vs neutral: The market is NOT pricing in pipeline risks — forward P/E of 16.1x is pricing in the bull case for pipeline success; when reality disappoints (one pipeline miss), estimates get cut and 16x forward becomes 20x forward on lower earnings
→ vs neutral: The 'coiled spring' narrative is a fantasy — capitulation requires RSI in 20s-30s, volume climax, panic selling; instead there's been orderly low-volume recovery and failed 50 SMA reclaim, which is distribution not accumulation
Support: 353.46 · 356.77 · 374 · 375 | Resistance: 399.55 · 411.22 · 444.12
AMGN is in a late-stage correction / early basing pattern within an intact secular uptrend (200 SMA at $356.77, price +10.2% above). The 50 SMA at $399.55 sits just above current price ($393.16), representing the key level to watch for a bullish reclaim. RSI is neutral at 45.12 (recovered from oversold), MACD remains bearish at -7.84 (signal -3.46, histogram -4.38 but narrowing), and Bollinger Bands show elevated width with lower band at $353.46. Price has basing between $374–$375 for 8+ sessions after a sharp -15% gap-down from $444.12 peak. VWMA at ~$395.36 shows equilibrium. No confirmed trend reversal yet—wait for decisive close above $399.55 or MACD bullish cross before committing capital.
Market Cap
$212.55 B
Share Price (52w High)
$447.03
Share Price (52w Low)
$269.77
50-Day Avg
$400.27
200-Day Avg
$360.35
P/E (TTM)
24.45x
Forward P/E
16.11x
PEG Ratio
2.32
Price / Book
18.19x
Beta
0.426
Dividend Yield
2.61%
Revenue (TTM)
$38.09 B
Gross Profit
$27.39 B
Gross Margin
71.9%
EBITDA
$17.27 B
EBITDA Margin
45.3%
Operating Income
$13.54 B
Operating Margin
35.5%
Net Income
$8.74 B
Net Margin
22.9%
EPS (TTM)
$16.08
Forward EPS
$24.40
ROE
91.5%
ROA
8.7%
Total Assets
$95.64 B
Total Liabilities
$83.95 B
Total Equity
$11.69 B
Cash & ST Investments
$13.99 B
Long-Term Debt
$51.86 B
Current Debt
$5.45 B
Total Debt
$57.30 B
Net Debt
$43.32 B
Current Ratio
1.37
Debt-to-Equity
490.3%
Working Capital
$9.46 B
Free Cash Flow (TTM)
$8.65 B
FCF as % of Revenue
22.7%
CapEx (Q2 2026)
$0.51 B
R&D (Q2 2026)
$1.87 B
SG&A (Q2 2026)
$1.75 B
Dividend (Quarterly)
$1.36 B
Q2 2026 Revenue
$9.54 B
Q2 2026 Operating Income
$3.51 B
Q2 2026 Net Income
$2.38 B
Q2 2026 Diluted EPS
$4.37
Q2 2026 FCF
$3.49 B
Book Value Per Share
$21.62
Intangibles / Goodwill
$39.2 B
Receivables (Q2 2026)
$10.23 B
Inventory (Q2 2026)
$6.22 B
Annual Dividend
$5.4 B
Strengths
Concerns
Amgen presents as a financially strong, cash-generative, defensive-growth biotech with TTM revenue of $38.09B, exceptional FCF of $8.65B (22.7% of revenue), and a reliable 2.61% dividend yield easily covered by cash generation. The balance sheet shows $13.99B in cash (up 74% YoY) offset by $57.30B in total debt, while Q2 2026 earnings are accelerating with revenue up 8.7% YoY. Primary risks include elevated leverage, high valuation multiples (P/B 18.19x), and significant intangibles of $39.2B that could face impairment headwinds.
Macro: Defensive positioning warranted: Polymarket pricing no 2026 Fed cuts at 96%, US recession at 6% (improving -3pp/wk), inflation >4.5% at 18% (rising +5pp/wk). Consumer sentiment "plummeting" per Zacks supports defensive rotation into big pharma. Modest stagflation tail risk; drug-pricing power provides partial hedge vs. CPI upside. Risk-on equity environment (BTC >$80k, Dow/Nasdaq records) but elevated cross-asset volatility.